OTTAWA, ON, May 3, 2025 –

Summary

• Product: JAMP-Pregabalin 50 mg capsules
• Issue: Health products – Product safety
• What to do: Inspect your medication bottle or packaging. If you have a prescription for 50 mg capsules and discover any 150 mg capsules in the bottle, or if you are uncertain, promptly return it to your pharmacy. If immediate return is not possible, seek guidance from your pharmacist or doctor. If you experience overdose symptoms (described below), get immediate medical help. Continue taking your pregabalin unless advised otherwise.

Images

Affected products

Issue

JAMP Pharma Corp. is recalling a specific batch of JAMP-Pregabalin because some bottles, though labeled for 50 mg capsules, might contain 150 mg capsules. This error could result in patients receiving a significantly higher dose than prescribed, potentially leading to an overdose and serious, possibly fatal, health consequences.

JAMP-Pregabalin is a prescription medication for adults, intended to alleviate nerve damage pain stemming from conditions like diabetes, shingles, or spinal cord injuries. It also addresses fibromyalgia-related pain.

Ingesting excessive pregabalin or rapidly escalating the dosage carries the risk of overdose, which can be life-threatening. Overdose symptoms may manifest as sudden mood alterations, drowsiness, confusion, depression, agitation, restlessness, and seizures. Furthermore, combining high doses of pregabalin with central nervous system depressants, such as opioids, has been linked to cardiac electrical irregularities, seizures, and mortality.

Patients should avoid abruptly discontinuing pregabalin, as this may trigger withdrawal symptoms like insomnia, nausea, headache, anxiety, excessive perspiration, diarrhea, and convulsions.

Health Canada is closely tracking the company’s recall efforts and investigations, including their implementation of corrective measures to prevent future occurrences. The public will be informed of any newly identified health risks.

What you should do

• Verify that your medication bottle contains only 50 mg capsules.
  • The 50 mg capsule is a white capsule with “PG” and “50” printed in black ink.
  • The 150 mg capsule is a white capsule with “PG” and “150” printed in black ink.
• If you find any 150 mg capsules, or are unsure, return the bottle to your pharmacy without delay. The pharmacist will inspect the capsules and provide a replacement if necessary.
• If you cannot immediately return the capsules to the pharmacy, consult your pharmacist or doctor for guidance.
• Seek immediate medical assistance if you experience any overdose symptoms (e.g., confusion, agitation, restlessness, or seizures).
• Do not discontinue pregabalin without consulting your doctor, as abrupt cessation can cause withdrawal symptoms.
• If you have queries regarding this recall, contact JAMP Pharma Corp. at 1-866-399-9091, extension 501, or via email at .
• Report any health product-related issues or to Health Canada.

Additional information for health professionals:

• Healthcare professionals, particularly pharmacists, are advised to inspect manufacturer’s 100-capsule bottles labeled as JAMP-Pregabalin 50 mg capsules before dispensing to ensure they do not contain 150 mg capsules. Report any unusual bottles or other issues to the company and to .

Également disponible en français

SOURCE Health Canada (HC)

“`